Next-gen CAR-T player steps on the gas with a $111M boost and a positive glimpse at early data
Though ImmPACT Bio was technically founded in Israel back in 2017, incoming CEO Sumant Ramachandra says the company was reborn last year when it merged with UCLA spinoff Kalthera. Now, with $111 million more to work with, the new chief executive is stepping on the gas.
ImmPACT Bio unveiled a massive Series B round early Thursday morning, along with a C-suite shakeup and a first glimpse at some Phase I data. Seven of eight patients with relapsed or refractory B cell non-Hodgkin’s lymphoma given the company’s lead candidate — a CD19/CD20 bispecific CAR-T — achieved complete remission after a median follow-up of 12 months, Ramachandra said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.